Literature DB >> 9917483

Perinatal risk factors for infant hospitalization with viral gastroenteritis.

R D Newman1, J Grupp-Phelan, D K Shay, R L Davis.   

Abstract

CONTEXT: A tetravalent vaccine against rotavirus, the most commonly identified etiologic agent of viral gastroenteritis (GE), has recently been licensed for use in the United States.
OBJECTIVE: To evaluate whether specific groups of infants might be at sufficiently high risk to warrant a focused rotavirus vaccine policy, we investigated perinatal risk factors for hospitalization with viral GE and rotavirus in the first year of life.
DESIGN: Population-based, case-control study.
SETTING: Washington State linked birth certificate and hospital discharge abstracts from 1987 through 1995. PATIENTS: Infants, 1 through 11 months of age, hospitalized for viral GE (N = 1606) were patients in this study. Control subjects were 8084 nonhospitalized infants, frequency-matched to patients on year of birth. PRIMARY OUTCOME MEASURE: Maternal and infant characteristics associated with infant hospitalization for viral GE.
RESULTS: We found a significant association between birth weight and the risk for hospitalization. Very low birth weight infants (<1500 g) were at the highest risk (odds ratio [OR] 2.6; 95% confidence interval [CI]: 1.6,4.1);, low birth weight infants (1500-2499 g), at intermediate risk (OR 1.6; 95% CI: 1.3,2.1); and large infants (>4000 g), at reduced risk (OR 0.8; 95% CI: 0.6,0.9). Other characteristics associated with GE hospitalization were male gender (OR 1.4; 95% CI: 1.3,1.6); maternal smoking (OR 1.2; 95% CI: 1.1,1. 4); unmarried mother (OR 1.2; 95% CI: 1.1,1.4); Medicaid insurance (OR 1.4; 95% CI: 1.3,1.7); and maternal age <20 years (OR 1.2; 95% CI: 1.0,1.5). Infants born October through December were at decreased risk for hospitalization (OR 0.8; 95% CI: 0.7,0.9), as were infants born to Asian mothers (OR 0.5; 95% CI: 0.3,0.7), and infants born to mothers >34 years of age (OR 0.7; 95% CI: 0.6,0.9). Using these factors, the area under a receiver operating characteristic curve was 0.63. Therefore, to achieve a sensitivity of 90% in identifying high-risk infants, specificity would fall to 10%. Subanalyses of children admitted for viral GE during the peak of the Northwest rotavirus season (January to March) and children with confirmed rotavirus infection demonstrated similar risk factors and receiver operating characteristic curves.
CONCLUSION: We conclude that a focused rotavirus vaccination policy using readily identifiable potential high-risk groups would be unlikely to prevent most infant hospitalizations associated with rotavirus infection. However, the safety of rotavirus vaccine in low birth weight and premature infants must be established, because these children appear to be at greater risk for hospitalization with viral GE and rotavirus.

Entities:  

Mesh:

Year:  1999        PMID: 9917483     DOI: 10.1542/peds.103.1.e3

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

Review 1.  Immunization of preterm infants.

Authors:  Arnaud Gagneur; Didier Pinquier; Caroline Quach
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Literature Review on Rotavirus: Disease and Vaccine Characteristics: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  E L Ford-Jones; S Calvin
Journal:  Can Commun Dis Rep       Date:  2010-11-30

3.  Updated Statement on the use of Rotavirus Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-07-16

4.  Self-efficacy as a mediator between maternal depression and child hospitalizations in low-income urban families.

Authors:  Margaret L Holland; Byung-Kwang Yoo; Harriet Kitzman; Linda Chaudron; Peter G Szilagyi; Helena Temkin-Greener
Journal:  Matern Child Health J       Date:  2011-10

Review 5.  Rotavirus vaccines: an overview.

Authors:  Penelope H Dennehy
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  Hospitalisation for rotavirus gastroenteritis in the paediatric population in the Veneto Region, Italy.

Authors:  Mario Saia; Aurore Giliberti; Giampietro Callegaro; Tatjana Baldovin; Marta Cecilia Busana; Francesco Pietrobon; Chiara Bertoncello; Vincenzo Baldo
Journal:  BMC Public Health       Date:  2010-10-22       Impact factor: 3.295

Review 7.  Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial.

Authors:  M Van der Wielen; P Van Damme
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-20       Impact factor: 3.267

8.  Effectiveness of monovalent and pentavalent rotavirus vaccine.

Authors:  Margaret M Cortese; Lilly Cheng Immergluck; Melissa Held; Shabnam Jain; Trisha Chan; Alexandra P Grizas; Saadia Khizer; Carol Barrett; Osbourne Quaye; Slavica Mijatovic-Rustempasic; Rashi Gautam; Michael D Bowen; Jessica Moore; Jacqueline E Tate; Umesh D Parashar; Marietta Vázquez
Journal:  Pediatrics       Date:  2013-06-17       Impact factor: 7.124

9.  Impact of rotavirus vaccine on premature infants.

Authors:  Jean-Michel Roué; Emmanuel Nowak; Grégoire Le Gal; Thomas Lemaitre; Emmanuel Oger; Elise Poulhazan; Jean-Dominique Giroux; Armelle Garenne; Arnaud Gagneur
Journal:  Clin Vaccine Immunol       Date:  2014-07-30

10.  Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children.

Authors:  Lilly Cheng Immergluck; Trisha Chan Parker; Shabnam Jain; Elham Laghaie; Philip Spandorfer; Robert C Jerris; Michael D Bowen; Umesh D Parashar; Margaret M Cortese
Journal:  J Pediatr       Date:  2016-02-28       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.